GREENLAND MINES LTD (GRML) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-14.22M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.65× | Operating cash flow / net income. Period ending 2026-06-30. $-14.22M ÷ $-21.77M ≈ 0.65× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -14.22M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -21.77M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-14.22M | (m) | (m) | (m) | (m) | $-21.77M | (m) | (m) | (m) | 0.65× |
| 2026-03-31 | (m) | (m) | $-9.31M | (m) | (m) | (m) | (m) | $-22.29M | (m) | (m) | (m) | 0.42× |
| 2025-12-31 | (m) | (m) | $-5.89M | (m) | (m) | (m) | (m) | $-10.55M | (m) | (m) | (m) | 0.56× |
| 2025-09-30 | (m) | (m) | $-5.55M | (m) | (m) | (m) | (m) | $-11.29M | (m) | (m) | (m) | 0.49× |
| 2025-06-30 | (m) | (m) | $-5.54M | (m) | (m) | (m) | (m) | $-11.35M | (m) | (m) | (m) | 0.49× |
| 2025-03-31 | (m) | (m) | $-4.48M | (m) | (m) | (m) | (m) | $-7.71M | (m) | (m) | (m) | 0.58× |
| 2024-12-31 | (m) | (m) | $-2.95M | (m) | (m) | (m) | (m) | $-6.15M | (m) | (m) | (m) | 0.48× |
| 2024-09-30 | (m) | (m) | $-3.02M | (m) | (m) | (m) | (m) | $-2.16M | (m) | (m) | (m) | 1.40× |
| 2024-06-30 | (m) | (m) | $-1.93M | (m) | (m) | (m) | (m) | $659.31K | (m) | (m) | (m) | -2.92× |
| 2024-03-31 | (m) | (m) | $-1.27M | (m) | (m) | (m) | (m) | $102.29K | (m) | (m) | (m) | -12.38× |
| 2023-12-31 | (m) | (m) | $-1.26M | (m) | (m) | (m) | (m) | $1.35M | (m) | (m) | (m) | -0.94× |
| 2023-09-30 | (m) | (m) | $-1.09M | (m) | (m) | (m) | (m) | $1.97M | (m) | (m) | (m) | -0.55× |
| 2023-06-30 | (m) | (m) | $-992.89K | (m) | (m) | (m) | (m) | $2.41M | (m) | (m) | (m) | -0.41× |
| 2023-03-31 | (m) | (m) | $-872.31K | (m) | (m) | (m) | (m) | $2.36M | (m) | (m) | (m) | -0.37× |
| 2022-12-31 | (m) | (m) | $-493.04K | (m) | (m) | (m) | (m) | $1.23M | (m) | (m) | (m) | -0.40× |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |